Horizon has announced agreements with three leading developers of diagnostic tests, for the development and/or supply of diagnostic reference standards. The agreements are expected to generate c. £2.2m of initial revenue, of which c. £2.1m will be recognised in the current year, with potential for additional revenue over time. We continue to believe that Horizon’s Products division (mainly X-MANTM cell lines and diagnostic reference standards) will remain the company’s key growth driver for the ....
